Table 3.
Erlotinib for patients with EGFR wild-type non-small-cell lung cancer
| Study | Country | Number of patients | Treatment line | EGFR mutational analyses | ORR (%) | Median PFS (months) | Median OS (months) | Reference |
|---|---|---|---|---|---|---|---|---|
| BR.21 (Phase III) | Global | 115 | Second or third | Direct sequencing | 6.9 | NA | 7.9 | 12, 29 |
| Okayama (Phase II) | Japan | 30 | Second, third, or fourth | PCR clamp assay | 3.3 | 2.1 | 9.2 | 30 |
| Hamamatsu (Phase II) | Japan | 20 | Third line | PCR clamp assay | 15 | 2.1 | 6.7 | 31 |
| TAILOR (Phase III) | Italy | 112 | Second line | Direct sequencing | 3 | 2.4 | 5.4 | 34 |
| DELTA (Phase III) | Japan | 109 | Second or third line | NA | 5.6 | 1.3 | 9.0 | 35 |
Abbreviations: DELTA, Docetaxel and Erlotinib Lung Cancer Trial; NA, not available; ORR, objective response rate; OS, overall survival; PCR, polymerase chain reaction; PFS, progression-free survival; TAILOR, TArceva Italian Lung Optimization tRial; EGFR, epidermal growth factor receptor.